ePulmonology Review

PH in the Clinic: The Revised Classifications

In this issue:

Pulmonary hypertension. The 2022 ESC/ERS revised guidelines have redefined it. New evidence from ongoing and completed clinical trials have led to updates in diagnostic thresholds and treatment algorithms. New agents — some approved, others advancing through the pipeline — promise improved efficacy and safety for a variety of patients. What does it all mean to practitioners in the clinic?

Join Dr. Catherine Simpson, from the Division of Pulmonary and Critical Care at the Johns Hopkins University School of Medicine, as she discusses how applying these new findings can improve patient outcomes in this issue of ePulmonology Review.

Learning objectives:

• Describe how changes to the 2022 ESC/ERS guidelines, including the revised classification of pulmonary hypertension and lowering the threshold for defining it, may impact clinical practice.

• Discuss how the revised 2022 ESC/ERS guidelines recommendation for inhalation therapy with treprostinil can affect management of PH due to interstitial lung disease (ILD).